Trinity Biotech plc (Trinity Biotech)develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The Company is a provider of raw materials to the life sciences industry and research institutes globally through the Company subsidiary, Fitzgerald Industries. It markets its portfolio of over 275 products to customers in 75 countries around the world. It markets its products in the United States through a direct sales force and in the rest of the world through a combination of direct selling and a network of distributors. On July 26, 2013, it acquired Immco Diagnostics Inc.
|Headquarters||IDA Business Park, Co Wicklow|
|Executive Chairman of the Board||Ronan O'Caoimh|
|Chief Financial Officer, Secretary||Kevin Tansley|
|Chief Operating Officer, Executive Director||Rory Nealon|
|Chief Scientific Officer, Executive Director||James Walsh|
|Non-Executive Director||Clinton Severson|
|Shares Out.||23.1M||Book Value||$7.85|
|Annual Dividend Rate||$0.20||Price/Sales (TTM)||6.2|
|Ex-Div Date||6/6/13||P/Cash Flow (TTM)||--|
|Pay Date||7/1/13||Operating Margin||19.90%|
*GAAP = prior to non-GAAP analyst adjusted earnings.